Compositions and methods for treating CNS disorders

A method of treating Alzheimer's disease in a patient in need thereof, comprising administering to a patient in need thereof a therapy including a first compound having the formula

• wherein R1 is (C1-C8) branched or unbranched alkyl;
• a (C1-C8) substituted or unsubstituted carbocyclic ring;
• branched or unbranched haloalkyl, a substituted or unsubstituted aryl, or a substituted or unsubstituted (CH2)p-aryl, where p is 1, 2, 3, or 4;
• R2 and R3, taken together, form a substituted or unsubstituted piperidine, pyrrolidine, azepane, aziridine, or azetidine ring;
• and n is 1, 2, 3, 4, 5 or 6;
• and pharmaceutically acceptable salts and/or esters thereof;
• and
• a second compound which is a cholinesterase or acetylcholinesterase inhibitor and is present in an amount which if administered alone does not substantially enhance memory.

A method of enhancing memory in a patient in need thereof, administering to a patient in need thereof a therapy including a first compound having the formula

• wherein R1 is (C1-C8) branched or unbranched alkyl;
• a (C1-C8) substituted or unsubstituted carbocyclic ring;
• branched or unbranched haloalkyl, a substituted or unsubstituted aryl, or a substituted or unsubstituted (CH2)p-aryl, where p is 1, 2, 3, or 4;
• R2 and R3, taken together, form a substituted or unsubstituted piperidine, pyrrolidine, azepane, aziridine, or azetidine ring;
• and n is 1, 2, 3, 4, 5 or 6;
• and pharmaceutically acceptable salts and/or esters thereof;
• and
• a second compound which is a cholinesterase or acetylcholinesterase inhibitor and is present in an amount which if administered alone does not substantially enhance memory.

A method of treating Alzheimer's disease in a patient in need thereof, comprising diagnosing a patient in need of treatment and administering to a patient in need thereof a therapy including a first compound having the formula

• wherein R1 is (C1-C8) branched or unbranched alkyl;
• a (C1-C8) substituted or unsubstituted carbocyclic ring;
• branched or unbranched haloalkyl, a substituted or unsubstituted aryl, or a substituted or unsubstituted (CH2)p, where p is 1, 2, 3, or 4;
• R2 and R3, taken together, form a substituted or unsubstituted piperidine, pyrrolidine, azepane, aziridine, or azetidine ring;
• and n is 1, 2, 3, 4, 5 or 6;
• and pharmaceutically acceptable salts and/or esters thereof, the first compound being present in an amount which if administered alone does not substantially enhance memory;
• and
• a second compound which is a cholinesterase or acetylcholinesterase inhibitor and is present in an amount which if administered alone does not substantially enhance memory.

A method of enhancing memory in a patient in need thereof, comprising diagnosing a patient in need of treatment and administering to a patient in need thereof a therapy including a first compound having the formula

• wherein R1 is (C1-C8) branched or unbranched alkyl;
• a (C1-C8) substituted or unsubstituted carbocyclic ring;
• branched or unbranched haloalkyl, a substituted or unsubstituted aryl, or a substituted or unsubstituted (CH2)p-aryl, where p is 1, 2, 3, or 4;
• R2 and R3, taken together, form a substituted or unsubstituted piperidine, pyrrolidine, azepane, aziridine, or azetidine ring;
• and n is 1, 2, 3, 4, 5 or 6;
• and pharmaceutically acceptable salts and/or esters thereof, the first compound being present in an amount which if administered alone does not substantially enhance memory;
• and
• a second compound which is a cholinesterase or acetylcholinesterase inhibitor and is present in an amount which if administered alone does not substantially enhance memory.

A pharmaceutical composition comprising

• a first compound of the formula
• wherein R1 is (C1-C8) branched or unbranched alkyl;
• a (C1-C8) substituted or unsubstituted carbocyclic ring;
• branched or unbranched haloalkyl, a substituted or unsubstituted aryl, or a substituted or unsubstituted (CH2)p-aryl, where p is 1, 2, 3, or 4;
• R2 and R3, taken together, form a substituted or unsubstituted piperidine, pyrrolidine, azepane, aziridine, or azetidine ring;
• and n is 1, 2, 3, 4, 5 or 6;
• and pharmaceutically acceptable salts and/or esters thereof;
• and
• a second compound which is a cholinesterase or acetylcholinesterase inhibitor, the first or second compound being present in an amount, which if administered alone, does not substantially enhance memory.